Harmony Biosciences shares are trading higher after the company was granted Orphan Drug designation for Pitolisant.
Portfolio Pulse from Benzinga Newsdesk
Harmony Biosciences has been granted Orphan Drug designation for Pitolisant, leading to a rise in its share prices.
September 07, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harmony Biosciences' stock is trading higher after the company received Orphan Drug designation for Pitolisant.
The Orphan Drug designation is a significant regulatory milestone that can lead to increased investor confidence and higher stock prices. This designation for Pitolisant has led to a surge in Harmony Biosciences' stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100